Microsatellite instability in cancer: a novel landscape for diagnostic and therapeutic approach

Defective DNA mismatch repair creates a strong mutator phenotype, recognized as microsatellite instability (MSI). Various next-generation sequencing-based methods for evaluating cancer MSI status have been established, and NGS-based studies have thoroughly described MSI-driven tumorigenesis. Accordi...

Full description

Saved in:
Bibliographic Details
Published in:Archives of toxicology 2020-10, Vol.94 (10), p.3349-3357
Main Authors: Yamamoto, Hiroyuki, Watanabe, Yoshiyuki, Maehata, Tadateru, Imai, Kohzoh, Itoh, Fumio
Format: Article
Language:English
Subjects:
Biomedical and Life Sciences
Biomedicine
Environmental Health
Occupational Medicine/Industrial Medicine
Pharmacology/Toxicology
Review Article
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Defective DNA mismatch repair creates a strong mutator phenotype, recognized as microsatellite instability (MSI). Various next-generation sequencing-based methods for evaluating cancer MSI status have been established, and NGS-based studies have thoroughly described MSI-driven tumorigenesis. Accordingly, high-frequency MSI (MSI-H) has been detected in 81 tumor types, including those in which MSI was previously underrated. The findings have increased the use of immunotherapy, which is assumed to be efficient in tumors having a high mutation burden and/or neoantigen load. In MSI tumorigenesis, positively and negatively selected driver gene mutations have been characterized in colorectal cancers. Recent advancements in genome-wide studies of MSI-H cancers have developed novel diagnostic and therapeutic approaches, including CXCR2 inhibitor, a synthetic lethal therapy targeting the Werner gene and inhibition of nonsense-mediated mRNA decay. MSI is a predictive marker for chemotherapy as well as immunotherapy. Thus, analyses of MSI status and MSI-related alterations in cancers are clinically relevant. We present an update on MSI-driven tumorigenesis, focusing on a novel landscape of diagnostic and therapeutic approaches.
ISSN:0340-5761
1432-0738
DOI:10.1007/s00204-020-02833-z